EP0705833B1 - Dc-89 derivat - Google Patents

Dc-89 derivat Download PDF

Info

Publication number
EP0705833B1
EP0705833B1 EP95916020A EP95916020A EP0705833B1 EP 0705833 B1 EP0705833 B1 EP 0705833B1 EP 95916020 A EP95916020 A EP 95916020A EP 95916020 A EP95916020 A EP 95916020A EP 0705833 B1 EP0705833 B1 EP 0705833B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
substituted
amino
unsubstituted
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95916020A
Other languages
English (en)
French (fr)
Other versions
EP0705833A4 (de
EP0705833A1 (de
Inventor
Nobuyoshi Amishiro
Satoru Nagamura
Hiromitsu Saito
Eiji Kobayashi
Akihiko Okamoto
Katsushige Gomi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to DK95916020T priority Critical patent/DK0705833T3/da
Publication of EP0705833A1 publication Critical patent/EP0705833A1/de
Publication of EP0705833A4 publication Critical patent/EP0705833A4/de
Application granted granted Critical
Publication of EP0705833B1 publication Critical patent/EP0705833B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to DC-89 derivatives.
  • the compounds of the present invention exhibit excellent anti-tumor activity and are useful as anti-tumor agents.
  • DC-89A1, DC-89A2, DC-89B1 and DC-89B2 represented by the following structural formula are known, and these compounds exhibit antibacterial activity against various bacteria and also antitumor activity against melanoma B-16, etc.
  • DC-89A1 is disclosed in WO87/06265, and DC-89A2, DC-89B1 and DC-89B2 are disclosed in JP,A,2-119787.
  • SF2582A and SF2582B which are the same compounds as DC-89A2 and DC-89A1, are disclosed in JP,A,1-139590.
  • DC-88A and DC113 are disclosed in WO87/06265 and JP,A,2-177890, respectively. These compounds exhibit not only antibacterial activity against various bacteria but also anti-tumor activity against melanoma B-16, etc.
  • DC-88A derivatives and DC-89 derivatives are disclosed in JP,A,2-288879, JP,A,3-7287, JP,A,3-128379 and JP,A,5-178858.
  • JP,A,3-128379 discloses Compounds (A) and (C) represented by the following formulae
  • JP,A,5-178858 discloses Compounds (B) and (D) represented by the following formulae.
  • CC-1065 and its derivatives are disclosed in JP,A,54-64695, JP,A,60-193989, WO88/04659, EP-359454 and JP,A,3-14581.
  • Related derivatives are disclosed in JP,A, 6-1162691, EP-537575 and EP-520435. It is an object of the present invention to provide DC-89 derivatives which exhibit excellent anti-tumor activity.
  • the present invention provides DC-89 derivatives represented by formula (I) wherein X represents Cl or Br; R represents substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 7 -C 20 aralkyl, COR 1 ⁇ in which R 1 represents hydrogen, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted aryl selected from the group consisting of phenyl and naphthyl, substituted or unsubstituted heterocyclic group selected from the group consisting of pyridyl, pyrazinyl and pyrimidinyl, OR 2 (in which R 2 represents substituted or unsubstituted C 1 -C 8 alkyl or aryl as defined above), SR 2 (in which R 2 has the same meaning as defined above), NR 3 R 4 (in which R 3 represents hydrogen, substituted C 1 -C 8 alkyl, amino, or mono- or di(C 1
  • Compounds (I) are hereinafter referred to as Compounds (I).
  • the compounds represented by formulae (I) to (IX) are referred to as Compounds (I) to (IX).
  • Compounds (I)a, (I)b, etc. are intended to be included in Compounds (I)
  • Compounds (I)b-1, (I)b-2, etc. are intended to be included in Compounds (I)b.
  • C 1 -C 8 alkyl and the alkyl moiety of mono- or di(C 1 -C 8 alkyl)amino consist of linear or branched alkyl groups having 1 to 8 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl and iso-octyl.
  • Aryl represents phenyl and naphthyl.
  • Aralkyl represents groups having 7 to 20 carbon atoms such as benzyl, phenetyl, styryl, benzhydryl and trityl.
  • the heterocyclic group is a pyridyl, pyrazinyl and pyrimidinyl.
  • the substituted C 1 -C 8 alkyl has 1 to 3 independently-selected substituents such as C 1 -C 8 alkoxy, C 1 -C 8 alkylthio optionally substituted by carboxy, (C 1 -C 8 alkoxy)carbonyl, benzyloxycarbonyl, amino, mono- or di(C 1 -C 8 alkyl)amino, cyclic amino optionally substituted by C 1 -C 8 alkyl or cyclic amino, halogen and phenyl, in which examples of the cyclic amino group include pyrrolidino, piperidino, piperazinyl and morpholino, and C 1 -C 8 alkyl and the C 1 -C 8 moiety of C 1 -C 8 alkoxy, C 1 -C 8 alkylthio, (C 1 -C 8 alkoxy)carbonyl and mono- or di(C 1 -C 8 alkyl)amino has the same definition as that of the above-menti
  • halogen examples include fluorine, chlorine, bromine and iodine atoms.
  • the substituted aryl, the substituted aralkyl and the substituted heterocyclic group each has 1 to 3 independently-selected substituents such as C 1 -C 8 alkyl, substituted C 1 -C 8 alkyl, C 1 -C 8 alkoxy, (C 1 -C 8 alkoxy)carbonyl, amino, mono- or di(C 1 -C 8 alkyl) amino, pyrrole and halogen, in which C 1 -C 8 alkyl and the alkyl moiety of (C 1 -C 8 alkoxy)carbonyl and mono- or di(C 1 -C 8 alkyl)amino has the same definition as that of the above-mentioned C 1 -C 8 alkyl, and the substituents of substituted C 1 -C 8 alkyl and halogen have the same meanings as defined above.
  • Examples of the pharmaceutically acceptable salts of Compounds (I) include inorganic acid-addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate and nitrate, and organic acid-addition salts such as acetate, benzoate, maleate, fumarate, succinate, tartrate, citrate, oxalate, glyoxylate, aspartate and methanesulfonate.
  • inorganic acid-addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate and nitrate
  • organic acid-addition salts such as acetate, benzoate, maleate, fumarate, succinate, tartrate, citrate, oxalate, glyoxylate, aspartate and methanesulfonate.
  • the processes can be easily carried out by using protection/deprotection method for functional groups conventionally employed in organic synthetic chemistry including oxidation, reduction and hydrolysis.
  • Compound (I)a which is Compound (I) wherein R is substituted or unsubstituted alkyl or substituted or unsubstituted aralkyl, can be prepared by the following process.
  • Compound (II) can be prepared by treating Compound (C) or Compound (D) with perchloric acid in an inert solvent.
  • Y has the same meaning as defined above.
  • Perchloric acid is usually used in an amount of 1 to 20 equivalents based on Compound (C) or (D).
  • inert solvent water, dimethylformamide, tetrahydrofuran, toluene, dioxane, acetonitrile, etc. may be used singly or in combination.
  • the reaction is usually conducted at -20°C to 50°C for 10 minutes to 10 hours.
  • Compound (IV) can be prepared by reacting Compound (II), in the presence of a base in an inert solvent, with R 9 -Hal (III) wherein R 9 is substituted or unsubstituted lower alkyl or substituted or unsubstituted aralkyl in the definition of R, and Hal is a chlorine, bromine or iodine atom.
  • R 9 and Y have the same meanings as defined above.
  • Compound (III) is usually used in an amount of 1 to 10 equivalents based on Compound (II).
  • the base include potassium carbonate, sodium hydrogen carbonate, potassium tert-butoxide, triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 10 equivalents based on Compound (II).
  • As the inert solvent dimethylformamide, acetone, tetrahydrofuran, toluene, dioxane, acetonitrile, etc. may be used singly or in combination.
  • the reaction is usually conducted at -20°C to 80°C for 1 hour to 3 days.
  • Compound (V) can be prepared by reacting Compound (IV) with methanesulfonyl chloride in the presence of a base in an inert solvent.
  • R 9 and Y have the same meanings as defined above.
  • Methanesulfonyl chloride is usually used in an amount of 1 to 5 equivalents based on Compound (IV).
  • the base include potassium tert-butoxide, triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 5 equivalents based on Compound (IV).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent pyridine, methylene chloride, chloroform, dimethylformamide, tetrahydrofuran, toluene, dioxane, etc. may be used singly or in combination.
  • the reaction is usually conducted at -80°C to 50°C for 30 minutes to 1 day.
  • Compound (I)a can be prepared by reacting Compound (V), in an inert solvent, with Met-X (VI) wherein Met is an alkali metal such as lithium, sodium and potassium, and X has the same meaning as defined above.
  • Met is an alkali metal such as lithium, sodium and potassium
  • X has the same meaning as defined above.
  • R 9 , Met, X and Y have the same meanings as defined above.
  • Compound (VI) is usually used in an amount of 1 to 20 equivalents based on Compound (V).
  • the inert solvent dimethylformamide, dimethylsulfoxide, tetrahydrofuran, toluene, dioxane, acetonitrile, etc. may be used singly or in combination.
  • the reaction is usually conducted at 0°C to 100°C for. 30 minutes to 2 days.
  • Compound (I)b which is Compound (I) wherein R is COR 1 in which R 1 has the same meaning as defined above, can be prepared by the following process.
  • Compound (VII) can be prepared by treating Compound (C) or Compound (D) with hydrochloric acid or hydrobromic acid in an inert solvent.
  • X and Y have the same meanings as defined above.
  • Hydrochloric acid or hydrobromic acid is usually used in an amount of 1 to 20 equivalents based on Compound (C) or (D).
  • the inert solvent water, dimethylformamide, tetrahydrofuran, dioxane, acetonitrile, etc. may be used singly or in combination.
  • the reaction is usually conducted at -30°C to 50°C for 10 minutes to 5 hours.
  • Compound (C) can be prepared from Compound (E) having the following structure, which is a precursor of Compound (C), by the process desclosed in JP,A,3-128379. Compound (C) thus obtained also may be used without isolation in the above process.
  • Me represents a methyl group
  • t-Bu represents a tert-butyl group.
  • Compound (I)b-1 which is Compound (I)b wherein R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group, can be prepared by reacting Compound (VII), in an inert solvent, with a condensation agent such as dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine and R 10 CO 2 H (in which R 10 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group in the definition of R 1 ).
  • DCC dicyclohexylcarbodiimide
  • R 10 CO 2 H in which R 10 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group in the definition of R 1 .
  • R 10 CO 2 H, DCC and 4-dimethylaminopyridine are usually used in amounts of 1 to 10 equivalents based on Compound (VII).
  • the inert solvent methylene chloride, chloroform, dimethylformamide, tetrahydrofuran, toluene, dioxane, acetonitrile, etc. may be used singly or in combination.
  • the reaction is usually conducted at -20°C to 50°C for 1 hour to 1 day.
  • Compound (I)b-1 can be prepared by reacting Compound (VII) with an acid anhydride represented by the formula (R 10 CO) 2 O in which R 10 has the same meaning as defined above in the presence of a base in an inert solvent.
  • R 10 , X and Y have the same meanings as defined above.
  • the acid anhydride is usually used in an amount of 1 to 10 equivalents based on Compound (VII).
  • the base include triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 10 equivalents based on Compound (VII).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent methylene chloride, chloroform, dimethylformamide, tetrahydrofuran, toluene, dioxane, pyridine, etc. may be used singly or in combination.
  • the reaction is usually conducted at - 20°C to 50°C for 30 minutes to 1 day.
  • Compound (I)b-2 which is Compound (I)b wherein R 1 is OR 2 or SR 2 in which R 2 has the same meaning as defined above, can be prepared by reacting Compound (VII) with R 2 -Z-COCl (VIII) wherein Z is oxygen or sulfur, and R 2 has the same meaning as defined above in the presence of a base in an inert solvent.
  • R 1 is OR 2 or SR 2 in which R 2 has the same meaning as defined above
  • Compound (VIII) is usually used in an amount of 1 to 10 equivalents based on Compound (VII).
  • the base include potassium tert-butoxide, triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 10 equivalents based on Compound (VII).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent methylene chloride, chloroform, dimethylformamide, tetrahydrofuran, toluene, dioxane, pyridine, etc. may be used singly or in combination.
  • the reaction is usually conducted at -80°C to 50°C for 30 minutes to 1 day.
  • Compound (I)b-3 which is Compound (I)b wherein R 1 is NR 3a R 4a wherein R 3a and R 4a independently represent hydrogen or substituted or unsubstituted lower alkyl in the definition of R 3 and R 4 , can be prepared by the following process.
  • Compound (IX) can be prepared by reacting Compound (VII) with p-nitrophenyl chloroformate in the presence of a base in an inert solvent.
  • X and Y have the same meanings as defined above.
  • p-Nitrophenyl chloroformate is usually used in an amount of 1 to 5 equivalents based on Compound (VII).
  • the base include potassium tert-butoxide, triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 5 equivalents based on Compound (VII).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent methylene chloride, chloroform, pyridine, dimethylformamide, tetrahydrofuran, toluene, dioxane, etc. may be used singly or in combination.
  • the reaction is usually conducted at -80°C to 30°C for 30 minutes to 10 hours.
  • Compound (I)b-3 can be prepared by reacting Compound (IX) with R 3 R 4 NH (in which R 3 and R 4 have the same meanings as defined above) in the presence of a base in an inert solvent.
  • R 3 and R 4 have the same meanings as defined above.
  • R 3 R 4 NH is usually used in an amount of 1 to 5 equivalents based on Compound (IX).
  • the base include triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 5 equivalents based on Compound (IX).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent methylene chloride, chloroform, dimethylformamide, tetrahydrofuran, toluene, dioxane, etc. may be used singly or in combination.
  • the reaction is usually conducted at -80°C to 80°C for 30 minutes to 1 day.
  • Compound (I)b-4 which is Compound (I)b wherein R 1 is NR 3b R 4b (in which R 3b and R 4b independently represent hydrogen, amino or mono- or di(lower alkyl)amino in the definition of R 3 and R 4 ) or (in which R 5 and R 6 have the same meanings as defined above), can be prepared by reacting Compound (IX), in the presence of a base in an inert solvent, with HNR 3b R 4b (X) a or wherein R 3b , R 4b , R 5 and R 6 have the same meanings as defined above.
  • R 11 is NR 3b R 4b (in which R 3b and R 4b have the same meanings as defined above) or (in which R 5 and R 6 have the same meanings as defined above) in the definition of R 1 , and X and Y have the same meanings as defined above.
  • Compound (X) is usually used in an amount of 1 to 5 equivalents based on Compound (IX).
  • the base include triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 5 equivalents based on Compound (IX).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent methylene chloride, chloroform, dimethylformamide, tetrahydrofuran, toluene, dioxane, etc. may be used singly or in combination.
  • the reaction is usually conducted at -80°C to 50°C for 30 minutes to 1 day.
  • Compound (I)c which is Compound (I) wherein R is SO 2 R 8 (in which R 8 has the same meaning as defined above), can be prepared by reacting Compound (VII), in the presence of a base in an inert solvent, with Compound (XI) represented by the formula R 8 SO 2 Cl (XI) wherein R 8 has the same meaning as defined above.
  • R 8 , X and Y have the same meanings as defined above.
  • Compound (XI) is usually used in an amount of 1 to 10 equivalents based on Compound (VII).
  • the base include potassium tert-butoxide, triethylamine, pyridine and 4-dimethylaminopyridine.
  • the base is usually used in an amount of 1 to 5 equivalents based on Compound (VII).
  • the base serves also as a solvent, it is used in large excess.
  • the inert solvent methylene chloride, chloroform, dimethylformamide, pyridine, tetrahydrofuran, toluene, dioxane, etc. may be used singly or in combination.
  • the reaction is usually conducted at -80°C to 50°C for 30 minutes to 20 hours.
  • the desired salt can be obtained by dissolving or suspending Compound (I) in a suitable solvent and adding a suitable acid to the solution or suspension.
  • reaction intermediates may be directly used in the subsequent step without isolation or purification.
  • Compounds (I) and its pharmaceutically acceptable salts may be in the form of adducts with water or various solvents, which are also within the scope of the present invention. Further, all possible isomers of Compounds (I) including optical isomers and mixtures thereof also fall within the scope of the present invention.
  • HeLaS 3 cells were suspended in MEM medium containing 10% fetal calf serum and 2 mM glutamine to a concentration of 2.67 x 10 4 cells/ml.
  • the cell suspension thus prepared was put into wells of a 24-well culture plate in an amount of 0.75 ml per well. After the cells were incubated in a CO 2 incubator overnight at 37°C, Compound (I) which had been appropriately diluted with a culture medium was added to each well in an amount of 0.25 ml.
  • the cells were further incubated in the CO 2 incubator for 72 hours, and the culture supernatant was removed. Then, the cells were dispersed in a solution of trypsin and EDTA, and recovered. The number of the cells was counted using a cell counter. The concentration of Compound (I) at which the growth of the cells is inhibited by 50% was calculated by comparing the number of untreated cells with the number of the cells treated with Compound (I) at known concentrations, and the value was defined as IC 50 .
  • mice Five male ddY-strain mice each weighing 18-20 g were used for each group as test animals, and 5 x 10 5 Sarcoma 180 tumor cells were implantedat the axilla subcutaneously.
  • 0.2 ml of a physiological saline containing Compound (I) at the concentration shown in Table 3 was intravenously administered to each mouse.
  • T/C T: average tumor volume (mm 3 ) of the group treated with the test compound, C: average tumor volume (mm 3 ) of the control group (to which 0.2 ml of a physiological saline was intravenously administered
  • Compound (I) was intravenously administered to ddY-strain male mice each weighing 20 ⁇ 1 g. MLD (minimum lethal dose) was determined by observing the mortality at 14 days after administration. The result is shown in Table 4.
  • Compounds (I) and pharmaceutically acceptable salts thereof can be used as anti-tumor compositions singly or in combination with at least one pharmaceutically acceptable auxiliary.
  • Compounds (I) or salts thereof are dissolved in a physiological saline or in an aqueous solution of glucose, lactose, mannitol, etc. to prepare a pharmaceutical composition suitable for injection.
  • Compounds (I) or salts thereof are freeze-dried in a conventional manner and mixed with sodium chloride to prepare a powder injection.
  • the pharmaceutical composition of the present invention may contain additives which are known in the art of medical preparation, for example, pharmaceutically acceptable salts.
  • composition of the present invention varies depending on the age, condition, etc. of a patient
  • Compound (I) is administered to mammals including human beings at a dose of 0.01 to 60 mg/kg/day. Administration may be conducted, for example, once a day (single administration or consecutive administrations) or intermittently 1 to 3 times a week or once every 2 to 3 weeks, intravenously. If desired, intraarterial administration, intraperitoneal administration, intrathoracial administration, etc. are also possible at a similar dose and in a similar manner. Further, if desired, the composition may also be administered orally, in a similar dose and in a similar manner.
  • Forms for oral administration include tablets, capsules, powders, granules and ampoules, which contain pharmaceutical auxiliaries well known in the art of medical preparation.
  • the present invention is illustrated by referring to the following Examples.
  • the physicochemical properties shown in the following Examples were determined with the following equipment.
  • silica-gel plate (Silica gel 60F 254s 0.5 mm 20 x 20 cm) manufactured by Merck Co. was used.
  • silica gel Wakogel C-200 manufactured by Wako Pure Chemical Industries, Ltd. was used.
  • the obtained crude product was dissolved in 2.6 ml of N,N-dimethylformamide, and 15.5 mg (0.178 mmol) of lithium bromide was added thereto. The mixture was stirred at 80'C for 3 hours. To the resulting reaction mixture was added a 0.01 M phosphate buffer (pH 7), and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • Ethylene dichloride (8ml) was added to the tert-butyl ester of Compound 13 (80 mg, 0.10 mmol), and 0.18 ml of 48% hydrobromic acid was added thereto. The mixture was stirred at 50°C for 4 hours.
  • To the reaction mixture was added a 1 N hydrobromic acid aqueous solution, and the mixture was extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was dissolved in 0.75 ml of methylene chloride, and 0.30 ml of methylene chloride containing 17.7 mg (0.143 mmol) of nicotinic acid and 29.6 mg (0.143 mmol) of dicyclohexylcarbodiimide was added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 17.5 mg (0.143 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 18.5 hours.
  • the obtained crude product was dissolved in 1.74 ml of methylene chloride, and 43.4 mg (0.215 mmol) of p-nitrophenyl chloroformate and 30 ⁇ l (0.215 mmol) of triethylamine were added thereto at -78°C. The mixture was stirred for 40 minutes. Subsequently, to the mixture was added 43 ⁇ l (0.359 mmol) of 1-amino-4-methylpiperazine, and the mixture was stirred at -78°C to 0°C for 24 hours. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the obtained crude product was dissolved in 1.74 ml of methylene chloride, and 43.4 mg (0.215 mmol) of p-nitrophenyl chloroformate and 30 ⁇ l (0.215 mmol) of triethylamine were added thereto at -78°C. The mixture was stirred for 35 minutes. Subsequently, to the mixture was added 34.6 ⁇ l (0.359 mmol) of 4-aminomorpholine, and the mixture was stirred at -78°C to room temperature for 23 hours. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the obtained crude product was dissolved in 1.31 ml of methylene chloride, and 24.9 mg (0.179 mmol) of 3-aminopyrazine-2-carboxylic acid and 37 mg (0.179 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 21.9 mg (0.179 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 18.5 hours. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the obtained crude product was dissolved in 1.45 ml of methylene chloride, and 27 mg (0.179 mmol) of 3,4-diaminobenzoic acid and 37 mg (0.179 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 10 minutes. Subsequently, to the mixture was added 21.9 mg (0.179 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 16 hours., To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • Acetonitrile (1.45 ml) and 33.8 ⁇ l of 48% hydrobromic acid were added to 25.0 mg (0.0597 mmol) of Compound D, and the mixture was stirred at room temperature for 50 minutes.
  • To the reaction mixture was further added 13.5 ⁇ l of 48% hydrobromic acid, and the mixture was stirred for 20 minutes.
  • To the reaction mixture was added a 1 N hydrobromic acid aqueous solution, and the resulting mixture was extracted with chloroform. The chloroform layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was dissolved in 0.94 ml of methylene chloride, and 0.37 ml of methylene chloride containing 29.6 mg (0.179 mmol) of 4-dimethylaminobenzoic acid and 37 mg (0.179 mmol) of dicyclohexylcarbodiimide was added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 21.9 mg (0.179 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 18 hours. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the obtained crude product was dissolved in 2.32 ml of methylene chloride, and 47.4 mg (0.287 mmol) of 3-dimethylaminobenzoic acid and 59.2 mg (0.287 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 35 mg (0.287 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 17.5 hours. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the chloroform layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was purified by thin-layer chromatography (chloroform) to give 43.8 mg of a crude product.
  • the obtained crude product was dissolved in 2.32 ml of methylene chloride, and 55.4 mg (0.287 mmol) of 4-diethylaminobenzoic acid and 59.2 mg (0.287 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 35 mg (0.287 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 21.5 hours. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the chloroform layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was dissolved in 2.32 ml of methylene chloride, and 40.3 mg (0.215 mmol) of 4-(1H-pyrrol-1-yl)benzoic acid and 44.4 mg (0.215 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 26.3 mg (0.215 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 17 hours and 15 minutes. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the chloroform layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was purified by column chromatography (chloroform) to give 29.3 mg of a crude product.
  • the obtained crude product was dissolved in 1.16 ml of methylene chloride, and 33.6 mg (0.143 mmol) of 4-(4-methylpiperazinylmethyl)benzoic acid and 29.6 mg (0.143 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 17.5 mg (0.143 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 21 hours and 15 minutes. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the obtained crude product was dissolved in 1.74 ml of methylene chloride, and 43.4 mg (0.215 mmol) of p-nitrophenyl chloroformate and 30 ⁇ l (0.215 mmol) of triethylamine were added thereto at -78°C. The mixture was stirred for 1.5 hours. Subsequently, to the mixture was further added 14.5 mg (0.0717 mmol) of p-nitrophenyl chloroformate, and the mixture was stirred for 30 minutes. Then, 27.2 ⁇ l (0.359 mmol) of 1,1-dimethylhydrazine was added thereto, and the mixture was stirred at -78° to -20°C for 24 hours.
  • the obtained crude product was dissolved in, 0.87 ml of methylene chloride, and 21.6 mg (0.107 mmol) of p-nitrophenyl chloroformate and 15 ⁇ l (0.107 mmol) of triethylamine were added thereto at -78°C. The mixture was stirred for 40 minutes. Subsequently, to the mixture was added 9.5 ⁇ l (0.179 mmol) of 1-methylhydrazine, and the mixture was stirred at -78°C to 0°C for 100 minutes. To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the obtained crude product was dissolved in 3.0 ml of methylene chloride, and 95.5 mg (0.474 mmol) of p-nitrophenyl chloroformate and 66 ⁇ l (0.474 mmol) of triethylamine were added thereto at -78°C, and the mixture was stirred for 45 minutes.
  • To the mixture was added 0.78 ml of a dichloromethane solution containing 101 mg (0.553 mmol) of 1-amino-4-piperidinopiperidine, and the mixture was stirred at 0°C to room temperature for 23.5 hours.
  • To the reaction mixture was added a saturated aqueous solution of sodium hydrogen carbonate, and the resulting mixture was extracted with chloroform.
  • the chloroform layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was dissolved in 1.74 ml of methylene chloride, and 54.1 mg (0.215 mmol) of 4-(tert-butoxycarbonylaminomethyl)benzoic acid and 44.4 mg (0.215 mmol) of dicyclohexylcarbodiimide were added thereto at -20°C. The mixture was stirred for 5 minutes. Subsequently, to the mixture was added 26.3 mg (0.215 mmol) of 4-dimethylaminopyridine, and the mixture was stirred at -20°C to room temperature for 5.5 hours. To the reaction mixture was added a 0.01 M phosphate buffer of pH 7, and the resulting mixture was extracted with chloroform.
  • the chloroform layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • 1,2-Dichloromethane (2.0 ml) and 1.445 g (0.893 mmol) of 5% hydrobromic acid in methanol were added to 65.4 mg (0.0717 mmol) of the crude product obtained in Example 34, and the mixture was stirred at 60°C for 5 hours and 45 minutes.
  • a saturated aqueous solution of sodium hydrogen carbonate was added to the reaction mixture, and the resulting mixture was extracted with chloroform.
  • the chloroform layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the obtained crude product was dissolved in 1.1 ml of methylene chloride, and 28.9 mg (0.143 mmol) of p-nitrophenyl chloroformate and 20 ⁇ l (0.143 mmol) of triethylamine were added thereto at -78°C. The mixture was stirred for 45 minutes. Then, to the mixture was added a solution of 31.8 mg (0.239 mmol) of 1,2-dimethylhydrazine dihydrochloride and 67 ⁇ l (0.478 mmol) of triethylamine in 0.31 ml of chloroform. The mixture was stirred at -20°C for 2 hours and 25 minutes.
  • the present invention relates to DC-89 derivatives.
  • the compounds of the present invention exhibit excellent anti-tumor activity and are useful as anti-tumor agents.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
  • Gyroscopes (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Jib Cranes (AREA)
  • Earth Drilling (AREA)
  • Video Image Reproduction Devices For Color Tv Systems (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (16)

  1. DC-89 Derivat, wiedergeben durch die Formel
    Figure 00910001
    worin X = Cl oder Br darstellt; R darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3R4 (worin R3 Wasserstoff, substituiertes C1-C8-Alkyl, Amino oder Mono- oder Di-(C1-C8alkyl)amino darstellt und R4 Amino oder Mono- oder Di-(C1-C8alkyl)amino darstellt),
    Figure 00910002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 00910003
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 00920001
    oder ein pharmazeutisch annehmbares Salz hiervon,
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, (C1-C8-Alkoxy)carbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl (das substituierte Alkyl hat 1 bis 3 unabhängig ausgewählte Substituenten, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, (C1-C8-Alkoxy)carbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl), C1-C8-Alkoxy, (C1-C8-Alkoxy)carbonyl, Amino, Mono- oder Di-(C1-C8-Alkylamino, Pyrrolyl und Halogen.
  2. DC-89 Derivat nach Anspruch 1, wiedergegeben durch die Formel:
    Figure 00920002
    worin X Cl oder Br darstellt; und Ra darstellt: COR1 {worin R1 substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, NR3R4 (worin R3 Wasserstoff, substituiertes C1-C8-Alkyl, Amino oder Monooder Di-(C1-C8-alkyl)amino darstellt und R4 Amino oder Monooder Di-(C1-C8-alkyl)amino darstellt),
    Figure 00930001
    (worin R6 und R7 unabhängig Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellen) oder
    Figure 00930002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder ein pharmazeutisch annehmbares Salz hiervon.
  3. DC-89 Derivat nach Anspruch 1, wiedergegeben durch die Formel:
    Figure 00930003
    worin X = Cl oder Br darstellt; und R1a darstellt:
    Figure 00930004
    (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt), oder
    Figure 00930005
    oder ein pharmazeutisch annehmbares Salz hiervon.
  4. DC-89 Derivat nach Anspruch 1, wiedergegeben durch die Formel:
    Figure 00940001
    worin X = Cl oder Br darstellt;
    R2a darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3aR4a (worin R3a substituiertes C1-C8-Alkyl, Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt und R4a Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt),
    Figure 00940002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 00940003
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 00950001
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(1-C8-alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  5. DC-89 Derivat, wiedergeben durch die Formel
    Figure 00950002
    worin X = Cl oder Br darstellt;
    R2b darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3bR4a (worin R3b Wasserstoff, Amino oder Monooder Di-(C1-C8-alkyl)amino darstellt und R4a Amino oder Monooder Di-(C1-C8-alkyl)amino darstellt),
    Figure 00960001
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 00960002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 00960003
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  6. DC-89 Derivat, wiedergeben durch die Formel
    Figure 00970001
    worin X = Cl oder Br darstellt;
    R2c darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3cR4a (worin R3c Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt und R4a Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt),
    Figure 00970002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 00970003
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 00980001
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8- Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  7. DC-89 Derivat, wiedergeben durch die Formel
    Figure 00980002
    worin X = Cl oder Br darstellt;
    R2d darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat),
    Figure 00990001
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 00990002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 00990003
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  8. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01000001
    worin X = Cl oder Br darstellt;
    R2e darstellt: COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimi-dinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat),
    Figure 01000002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01000003
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)), oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 01010001
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8- Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  9. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01010002
    worin X = Cl oder Br darstellt;
    R2f darstellt: COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe,
    Figure 01010003
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01020001
    (worin R6 dieselbe Bedeutung, wie oben definiert, halt)}; und
    Y darstellt:
    Figure 01020002
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di- (C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unahbängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8- Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  10. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01020003
    worin X = Cl oder Br darstellt;
    R darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituier-tes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3R4 (worin R3 Wasserstoff, substituiertes C1-C8-Alkyl, Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt und R4 Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt),
    Figure 01030001
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01030002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Ya darstellt:
    Figure 01030003
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8- Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  11. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01040001
    worin X = Cl oder Br darstellt;
    R2a darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3aR4a (worin R3a substituiertes C1-C8-Alkyl, Amino oder Mono- oder Di-(C1-C8-alkyl)amino dar-stellt und R4a Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt),
    Figure 01040002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01050001
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 01050002
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl,C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  12. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01050003
    worin X = Cl oder Br darstellt;
    R2b darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes
    Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyräzinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3bR4a (worin R3a Wasserstoff, substituiertes C1-C8-Alkyl, Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt und R4a Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt),
    Figure 01060001
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01060002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 01060003
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  13. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01070001
    worin X = Cl oder Br darstellt;
    R2c darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat), NR3cR4a (worin R3c Amino oder Mono- oder Di-(C1-C8-alkyl)amino darstellt und R4a Amino oder Mono- oder Di(C1-C8-alkyl)amino darstellt),
    Figure 01070002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01080001
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Y darstellt:
    Figure 01080002
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  14. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01080003
    worin X = Cl oder Br darstellt;
    R2d darstellt: substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes C7-C20-Aralkyl, COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat),
    Figure 01090001
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01090002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Ya darstellt:
    Figure 01090003
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  15. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01100001
    worin X = Cl oder Br darstellt;
    R2e darstellt: COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe, substituierte oder unsubstituierte heterocyclische Gruppe, ausgewählt aus der aus Pyridyl, Pyrazinyl und Pyrimidinyl bestehenden Gruppe, OR2 (worin R2 substituiertes oder unsubstituiertes C1-C8-Alkyl oder Aryl, wie oben definiert, darstellt), SR2 (worin R2 dieselbe Bedeutung, wie oben definiert, hat),
    Figure 01100002
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01100003
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, oder SO2R8 (worin R8 substituiertes oder unsubstituiertes C1-C8-Alkyl oder substituiertes oder unsubstituiertes Aryl, wie oben definiert, darstellt); und Ya darstellt:
    Figure 01110001
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
  16. DC-89 Derivat, wiedergeben durch die Formel
    Figure 01110002
    worin X = Cl oder Br darstellt;
    R2f darstellt: COR1 {worin R1 Wasserstoff, substituiertes oder unsubstituiertes C1-C8-Alkyl, substituiertes oder unsubstituiertes Aryl, ausgewählt aus der aus Phenyl und Naphthyl bestehenden Gruppe,
    Figure 01120001
    worin R5 = NR7 (worin R7 Wasserstoff oder substituiertes oder unsubstituiertes C1-C8-Alkyl darstellt) oder Sauerstoff darstellt, und R6 dieselbe Bedeutung, wie oben für R7 definiert, hat, oder
    Figure 01120002
    (worin R6 dieselbe Bedeutung, wie oben definiert, hat)}, und Ya darstellt:
    Figure 01120003
    wobei:
    das Alkyl, falls substituiert, 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkoxy, C1-C8-Alkylthio, wahlweise substituiert mit Carboxy, Carboxy, C1-C8-Alkoxycarbonyl, Benzyloxycarbonyl, Amino, Mono- oder Di-(C1-C8-alkyl)amino, cyclisches Amino, wahlweise substituiert mit C1-C8-Alkyl oder cyclischem Amino, Halogen und Phenyl,
    und
    die Aryl-, Aralkylgruppe und heterocyclische Gruppe, falls substituiert, jede 1 bis 3 unabhängig ausgewählte Substituenten hat, die umfassen: C1-C8-Alkyl, substituiertes C1-C8-Alkyl, C1-C8-Alkoxy, C1-C8-Alkoxycarbonyl, Amino, Mono- oder Di-(C1-C8-Alkyl)amino, Pyrrolyl und Halogen,
    oder ein pharmazeutisch annehmbares Salz hiervon.
EP95916020A 1994-04-22 1995-04-20 Dc-89 derivat Expired - Lifetime EP0705833B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK95916020T DK0705833T3 (da) 1995-04-20 1995-04-20 DC-89-derivat

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP8471494 1994-04-22
JP8471494 1994-04-22
JP84714/94 1994-04-22
PCT/JP1995/000779 WO1995029179A1 (en) 1994-04-22 1995-04-20 Dc-89 derivative

Publications (3)

Publication Number Publication Date
EP0705833A1 EP0705833A1 (de) 1996-04-10
EP0705833A4 EP0705833A4 (de) 1997-04-02
EP0705833B1 true EP0705833B1 (de) 2004-07-21

Family

ID=13838345

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916020A Expired - Lifetime EP0705833B1 (de) 1994-04-22 1995-04-20 Dc-89 derivat

Country Status (10)

Country Link
US (1) US5641780A (de)
EP (1) EP0705833B1 (de)
KR (1) KR100350260B1 (de)
AT (1) ATE271557T1 (de)
AU (1) AU685939B2 (de)
CA (1) CA2165819C (de)
DE (1) DE69533277T2 (de)
ES (1) ES2220927T3 (de)
PT (1) PT705833E (de)
WO (1) WO1995029179A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134597A (en) * 1996-09-03 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Dc-89 derivatives
NZ504884A (en) * 1997-12-08 2002-10-25 Scripps Research Inst Synthesis of the dihydroindole C-ring of CC-1065/duocarmycin analogs and certain intermediates
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
US7129261B2 (en) * 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
NZ556661A (en) * 2005-02-18 2010-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
EP3058955B1 (de) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Ov064-bindende antikörper und verfahren zu deren verwendung
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
SI1940789T1 (sl) 2005-10-26 2012-03-30 Medarex Inc Postopki in spojine za pripravo cc analogov
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
CA2678514A1 (en) * 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
BRPI0819765A2 (pt) * 2007-11-30 2015-05-05 Bristol Myers Squibb Co Conjugados de anticorpos anti-rg-1
EP2998405B1 (de) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human-cd52-immunglobuline
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
EP3029066B1 (de) 2010-07-29 2019-02-20 Xencor, Inc. Antikörper mit modifizierten isoelektrischen punkten
EP3828205A1 (de) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1-antikörper
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
UA114478C2 (uk) 2011-06-28 2017-06-26 Берлін-Хемі Аг Антитіло, яке специфічно зв'язується з bst1
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2970486B1 (de) 2013-03-15 2018-05-16 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
SI3055331T1 (sl) 2013-10-11 2021-04-30 Oxford Bio Therapeutics Limited Konjugirana protitelesa proti LY75 za zdravljenje raka
CA2938919C (en) 2014-02-28 2020-12-29 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
FI3319936T3 (fi) 2015-07-12 2026-03-12 Hangzhou Dac Biotech Co Ltd Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
CA3042442C (en) 2016-11-14 2024-01-02 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
TW202519260A (zh) 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
EP3861016A2 (de) 2018-10-03 2021-08-11 Xencor, Inc. Il-12-heterodimere fc-fusionsproteine
UA128825C2 (uk) 2019-03-01 2024-10-30 Ксенкор, Інк. Гетеродимерні антитіла, що зв'язують enpp3 та cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520435A2 (de) * 1991-06-28 1992-12-30 Kyowa Hakko Kogyo Co., Ltd. Derivate der Verbindung DC 89

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
EP0340243B1 (de) * 1986-12-19 1994-09-28 The Upjohn Company Cc-1065 analoge
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
JPH05178858A (ja) * 1991-06-28 1993-07-20 Kyowa Hakko Kogyo Co Ltd Ｄｃ−８９誘導体
JPH0597853A (ja) * 1991-10-07 1993-04-20 Kyowa Hakko Kogyo Co Ltd Ｄｃ−８９誘導体の臭化水素酸塩

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520435A2 (de) * 1991-06-28 1992-12-30 Kyowa Hakko Kogyo Co., Ltd. Derivate der Verbindung DC 89

Also Published As

Publication number Publication date
PT705833E (pt) 2004-11-30
US5641780A (en) 1997-06-24
CA2165819C (en) 2005-12-27
AU685939B2 (en) 1998-01-29
ATE271557T1 (de) 2004-08-15
ES2220927T3 (es) 2004-12-16
AU2267195A (en) 1995-11-16
KR960702464A (ko) 1996-04-27
DE69533277T2 (de) 2005-07-21
CA2165819A1 (en) 1995-11-02
EP0705833A4 (de) 1997-04-02
EP0705833A1 (de) 1996-04-10
KR100350260B1 (ko) 2003-01-06
WO1995029179A1 (en) 1995-11-02
DE69533277D1 (de) 2004-08-26

Similar Documents

Publication Publication Date Title
EP0705833B1 (de) Dc-89 derivat
EP0406749B1 (de) DC-88A-Derivate
US5736549A (en) Hypoxanthine and guanine compounds
US5187186A (en) Pyrroloindole derivatives
US4923986A (en) Derivatives of physiologically active substance K-252
US5344926A (en) Process for producing staurosporine derivatives
MXPA97002488A (en) Compounds of purine and guanine as inhibitors of
US4889859A (en) Pyrido[2,3-d]pyrimidine derivatives
EP0468400B1 (de) DC-89-Derivate als Antitumor-Wirkstoffe
JPH05247055A (ja) スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
US5258383A (en) DC-89 derivatives
US5670492A (en) DC-89 derivatives
US5214065A (en) Dc-89 derivatives
US6310210B1 (en) Camptothecin derivatives
US5248692A (en) DC-89 derivatives as anti-tumor agents
EP0369749B1 (de) Antitumor-Verbindungen
US5220026A (en) Pyrazoloacridone derivatives
CA2163890A1 (en) Dc-89 derivative
EP0499130A1 (de) Derivate der Verbindung DC-89
JPH0551384A (ja) Ｄｃ−８９誘導体
JPWO1995029179A1 (ja) Ｄｃ−８９誘導体
JPH05178858A (ja) Ｄｃ−８９誘導体
US5218126A (en) Halogen substituted mitomycin derivatives
US4215121A (en) Pyrazine substituted ureas
JPH05208979A (ja) Ｄｃ１１３誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

K1C1 Correction of patent application (title page) published

Effective date: 19960410

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19981210

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

XX Miscellaneous (additional remarks)

Free format text: A REQUEST FOR CORRECTION OF THE DESCRIPTION IN PAGE 48 HAS BEEN FILED PURSUANT TO RULE 88 EPC. A DECISIONON THE REQUEST WILL BE TAKEN DURINGTH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69533277

Country of ref document: DE

Date of ref document: 20040826

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040403253

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20040928

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2220927

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050422

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20070316

Year of fee payment: 13

Ref country code: AT

Payment date: 20070316

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20070319

Year of fee payment: 13

Ref country code: MC

Payment date: 20070319

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20070320

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20070321

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20070327

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070410

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20070412

Year of fee payment: 13

Ref country code: CH

Payment date: 20070412

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20070508

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20070608

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070410

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20070627

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20070323

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070313

Year of fee payment: 13

BERE Be: lapsed

Owner name: *KYOWA HAKKO KOGYO CO. LTD

Effective date: 20080430

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20081020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080420

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20081101

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081020

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081101

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081101

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080421

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20080421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081104

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080421